Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Molecular aberrations and epigenetic dysregulation in NK-LGL leukemia

Marco Herling • 12 Jun 2022
EHA 2022
Leukemia Natural Killer Large Granular Lymphocyte Leukemia Rare Diseases

Marco Herling, MD, University of Leipzig, Leipzig, Germany, discusses the pathogenesis of chronic natural killer large granular lymphocyte (NK-LGL) leukemia, commenting on the molecular landscape of this disease. Dr Herling explains that this disease is characterized by constitutive JAK/STAT signaling, with a large proportion of patients carrying mutations in TET2 or STAT3, thereby suggesting this pathway as a potential therapeutic target. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Marco Herling

1:00
Unmet needs in BPDCN: CNS involvement & the importance of intrathecal chemotherapy prophylaxis
Marco Herling • 25 Apr 2023
1:41
Improvements in the awareness and diagnosis of BPDCN
Marco Herling • 25 Apr 2023
1:15
Managing patients with transplant-ineligible BDPCN with tagraxofusp
Marco Herling • 25 Apr 2023
1:23
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
Marco Herling • 25 Apr 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals